New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼(Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
Findings presented at the 31st European Congress of Psychiatry (EPA 2023) confirm the importance of…
How Real-Time AI Builds Trust in Customer Conversations at Scale
Data Privacy Week: Solidatus Warns Compliance Alone Isn’t Enough
RentRedi Expands Its Accounting Suite With Smarter Tax-Ready Tracking